Last updated: March 7, 2026
What Is the Drug Identified by NDC 00456-1512?
NDC 00456-1512 corresponds to Rivastigmine Transdermal Patch, marketed under the brand name Exelon. It is prescribed for the treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease.
Market Size and Demand Dynamics
Current Usage and Market Penetration
- Prescription Volume: Approximately 8 million prescriptions annually in the U.S., according to IQVIA data (2022).
- Patient Population: Estimated 2.5 million patients with Alzheimer’s or Parkinson’s disease globally.
- Key Markets: U.S., Europe, Japan account for over 85% of sales.
Competitive Landscape
- Competing Drugs: Donepezil (Aricept), Galantamine (Razadyne), and newer agents like Aducanumab.
- Market Share: Rivastigmine transdermal patches held roughly 20-25% of the cholinesterase inhibitors market, with oral formulations dominating at 60-70%.
Regulatory and Reimbursement Environment
- FDA Approval: Approved in 2000.
- Reimbursement Trends: Full coverage under Medicare Part D and majority of private insurers.
Price Trajectory and Projections
Current Price Benchmarks
| Formulation |
Average Wholesale Price (AWP) |
Estimated Outpatient Cost (USD) |
| 4.6 mg/24 hr Patch (monthly) |
$500 |
$600 |
| 9.5 mg/24 hr Patch (monthly) |
$700 |
$850 |
| 13.3 mg/24 hr Patch (monthly) |
$850 |
$1,050 |
(Prices based on July 2023 estimates)
Historical Price Trends
- Price for the 4.6 mg patch stable from 2015 to 2019.
- Slight price increases observed post-2020, with annual growth around 3-4%.
Factors Influencing Future Prices
- Generic Entry: Generic rivastigmine patches entered the market in Europe in 2022, exerting downward pressure on brand prices.
- New Formulations: Development of more convenient or longer-acting patches could impact pricing strategies.
- Inflation and Regulatory Costs: Yearly increases in manufacturing, R&D, and compliance expenses may lead to modest price adjustments.
Projected Price Range (Next 5 Years)
| Year |
Estimated Average Wholesale Price (USD) |
Rationale |
| 2024 |
$520 - $560 |
Stable post-generic entry, small inflation adjustment |
| 2025 |
$530 - $580 |
Slight increase expected amid competitive pressures |
| 2026 |
$550 - $600 |
New formulation launches or phased price increases |
| 2027 |
$560 - $620 |
Continued market maturation, inflation effects |
| 2028 |
$570 - $640 |
Potential stabilized prices with competitive pressures |
Competitive and Market Entry Risks
- Emergence of Once-Daily Oral Formulations: Could replace transdermal patches if proven more convenient.
- Pricing Strategies of Generics: May induce aggressive pricing, pressuring branded product margins.
- Regulatory Changes: Any updates to reimbursement policies or patent extensions could impact revenue.
Key Takeaways
- Market Size: Approximate 8 million prescriptions annually in the U.S. and strong international presence.
- Current Pricing: Wholesale prices range from $500 to $850 per month depending on dose.
- Trends: Prices have been stable with minor increases; generics threaten upward pricing pressure.
- Future Prices: Expected to hover around $520-$640 over the next five years with slight upward adjustments.
- Market Risks: Competition from generics and alternative formulations, regulatory changes.
FAQs
1. What are the primary drivers of the Rivastigmine patch’s price?
Manufacturing costs, R&D expenses, approval status, and payer reimbursement policies influence pricing.
2. How likely are generic versions to impact prices?
High: Generics launched in key markets, including Europe, in 2022, will exert downward pressure on brand prices.
3. Will new formulations replace patches soon?
Possibly, if they demonstrate superior convenience or efficacy, but current evidence suggests patches will maintain market share for the next few years.
4. How does the market size compare between regions?
U.S. dominates with roughly 60% of total prescriptions, followed by Europe and Japan.
5. What is the outlook for pricing in the next five years?
Prices are expected to slightly increase or stabilize, influenced by generics, competition, and costs.
References
[1] IQVIA. (2022). Prescription Trends in the U.S.
[2] FDA. (2000). Approval of Rivastigmine for dementia.
[3] MarketWatch. (2023). Pharmaceutical Pricing Trends Report.
[4] GlobalData. (2023). Alzheimer's Disease Market Insights.
[5] Medicare.gov. (2023). Drug coverage policies.
